ReachRxResearch
Home
Research
Sign Up
Delayed foveal atrophy following early visual improvement after voretigene neparvovec gene therapy in a child
Back to Research Hub
  1. Home
  2. Research Hub
  3. Delayed foveal atrophy following early v…

Delayed foveal atrophy following early visual improvement after voretigene neparvovec gene therapy in a child

Eye·September 3
OphthalmologySafety signalLeber Congenital AmaurosisRPE65-Associated Inherited Retinal DystrophyCase ReportGene TherapyAdolescentLuxturnaVoretigene Neparvovec

Summary

View source

What was studied

A single case of a 13-year-old male with biallelic RPE65-IRD who received bilateral voretigene neparvovec (VN) without subretinal foveal detachment, followed for approximately 4 years to assess long-term visual and structural outcomes.

Key findings

Initial BCVA improved by 3–4 lines (to 0.20–0.30 logMAR) and FST improved up to -39.1 dB at 6 weeks; by ~4 years, BCVA had declined markedly (0.68–0.90 logMAR) and FST worsened to -18.2 to -22.8 dB, with OCT showing foveal outer retinal atrophy and chorioretinal atrophy (CRA) along the vascular arcade.

Study limitations

Single case report with no comparator; causality between VN treatment (vs. natural disease progression) and CRA cannot be established; immunosuppression protocol details are not fully described.

Clinical implications

Patients treated with voretigene neparvovec should be monitored long-term, as delayed foveal atrophy can emerge years after initial visual gains. Those with large early FST improvements may warrant modified or extended immunosuppression to reduce CRA risk.

Caveats

  • Natural disease progression of RPE65-IRD cannot be fully excluded as a contributor to the observed late deterioration without a control or comparator.
  • The brand name Luxturna is not explicitly mentioned in the paper but is the proprietary name for voretigene neparvovec; tagged accordingly.
  • This is a single case report (n=1); findings cannot be generalized and causality between VN treatment and CRA is not established.

Related Questions

Explore related topics

What is the risk of chorioretinal atrophy after voretigene neparvovec gene therapy?Should immunosuppression be extended after voretigene neparvovec based on FST response?How does RPE65-IRD naturally progress compared to post-voretigene neparvovec deterioration?

Publication Details

Year
2026
Journal
Eye
Sample Size
n=1
Source
View article
Keep scrolling
More content below.
Up Next